|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies of IL-17 inhibitors for other indications including psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and asthma yielded similar results.
|
30900514 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides the established treatment of anti-TNF antibodies and ustekinumab for psoriatic arthritis, the newer treatment options of IL17 antibodies and apremilast are also effective for the treatment of psoriatic arthritis.
|
30735612 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A (IL-17A), IL-17F, IL-23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927).
|
31070869 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
|
30858782 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ixekizumab is a humanized monoclonal antibody directed against IL-17A and it has been approved for the treatment of moderate-to-severe plaque psoriasis, and recently also psoriatic arthritis.
|
30589394 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Improved knowledge of the immune/inflammatory pathways, which characterise the pathophysiology of rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have provided the link between inflammation and bone loss, via a complex network of bone cells, T and B cells, pro-inflammatory cytokines such as TNF-α, IL1, IL6, IL17, IL23, costimulator molecules, signalling pathways including both RANKL/RANK/OPG and Wnt signallings.
|
30557124 |
2019 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis.
|
30458922 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCL4 is a novel inducer of human Th17 cells and correlates with IL-17 and IL-22 in psoriatic arthritis.
|
29193036 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of IL-17 in the Human Immune System and Its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.
|
29742185 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mannan-induced Nos2 in macrophages enhances IL-17-driven psoriatic arthritis by innate lymphocytes.
|
29774240 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both IL-17A and IL-22 produced by Th17 cells appear to play critical roles in promoting the cutaneous and musculoskeletal inflammation that characterizes PsA.
|
29439292 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviews the immunologic role of interleukin (IL)-17, the major effector cytokine in the pathogenesis of psoriatic disease, along with the rationale for targeting the IL-17 cytokine family (IL-17A, IL-17F, and IL-17 receptor A) in the treatment of psoriasis and psoriatic arthritis.
|
30109481 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17 inhibition by secukinumab over 24 weeks led to a significant decrease of synovial inflammation and no progression of catabolic and anabolic bone changes in the joints of patients with PsA.
|
30053825 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA).
|
29550766 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rheumatoid and psoriatic arthritis are chronic inflammatory diseases, with massive increase of cardiovascular events (CVE), and contribution of the cytokines TNF-α and IL-17.
|
29195855 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indeed, the therapy targeting IL-17 has been approved or is in clinical trials, and proved to be very efficient to treat psoriasis, psoriatic arthritis and ankylosing sclerosis.
|
30133701 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the efficacy and safety of ixekizumab (IXE), an interleukin 17A antagonist, in patients with psoriatic arthritis (PsA) after 52 weeks in a phase III study.
|
29247148 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The unique bone phenotype that occurs in PsA and AS is a surprising coexistence of both systemic bone loss and periosteal and entheseal bone formation and is likely to be the result of the actions of IL-23 and/or IL-17 on bone.
|
30266977 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increase of Th1 (IFNγ: PsA = 37.1 pg/mL vs. CS = 17 pg/mL, p < 0.05; TNFα: PsA = 24.6 pg/mL vs. CS = 9.8 pg/mL, p < 0.0001) and Th17 cytokine profiles (IL-17: PsA = 6.4 pg/mL vs. CS = 2.7 pg/mL, p < 0.05; IL-22: PsA = 8.4 pg/mL vs. CS = 1.8 pg/mL, p < 0.001), were found in PsA patients.
|
28965181 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: IL-12/23 inhibition appears to be a good first-line option for plaque PsO, but efficacy in PsA does not compare favorably to IL-17 inhibition.
|
29949399 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/IL-17 axis is central to the pathogenesis of psoriatic arthritis (PsA).
|
29148410 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.
|
29444376 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The T-helper (Th)-17 pathway and the interleukin (IL)-23/IL-17 axis have become prominent players in PsA and considerably increased our understanding of disease pathogenesis.
|
30263103 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secukinumab (anti-interleukin-17A [anti-IL-17A]) is an effective therapy for ankylosing spondylitis and psoriatic arthritis, the prototypical forms of spondyloarthritis (SpA).
|
29869838 |
2018 |
|
Arthritis, Psoriatic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
|
29275332 |
2018 |